Results 171 to 180 of about 29,072 (265)

An Update on Invasive Fungal Infections in Solid Organ Transplant Recipients

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT Invasive fungal infections (IFI) remain a significant infection‐related complication in solid organ transplant recipients (SOTRs), the incidence of which has not changed overtime. With a focus on studies and data published after 2019, this narrative review provides an update on the epidemiology and prevention of IFIs in SOTRs and highlights ...
Tina Marinelli, Shahid Husain
wiley   +1 more source

Liver transplantation under cyclosporine: a decade of experience. [PDF]

open access: yes, 1991
Fung, JJ   +7 more
core  

Efficiency and Safety of Endoscopic Injection Sclerotherapy With Ligation for Esophageal Varices: A Retrospective Study.

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Endoscopic injection sclerotherapy with ligation (EISL) is a combined endoscopic treatment that involves endoscopic injection sclerotherapy (EIS) and endoscopic variceal ligation. This study aimed to compare the efficacy of conventional EIS and EISL in treating esophageal varices and the usefulness of EISL.
Keita Maki   +6 more
wiley   +1 more source

[Primary biliary cirrhosis: liver transplantation].

open access: yesNihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999
M, Hirata, Y, Harihara, M, Makuuchi
openaire   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott   +10 more
wiley   +1 more source

The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 6, Page 1379-1387, June 2026.
ABSTRACT Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020.
Abhilasha Borad   +9 more
wiley   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub   +5 more
wiley   +1 more source

Mechanisms of Gui Zhi Fu Ling Formula in Liver Fibrosis: Metabolomics and Gut Microbiota Analysis

open access: yeseFood, Volume 7, Issue 3, June 2026.
Our study was based on the efficacy of the phenotype in an animal model and used multi‐omics to explore the mechanism of action of the compound. We found that Gui Zhi Fu Ling Formula may ameliorate hepatic fibrosis potentially associated with increased hepatic EPA and the expression of gut Pseudomonas.
Xiaoliang Deng   +5 more
wiley   +1 more source

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy